

January 9, 2013

Dear Nuclear Medicine Professional,

We have additional information to share regarding the operational status of the Dutch High-Flux Reactor (HFR). We have been informed by NRG, the operator of the HFR, that they continue to assess the necessary steps they must take before bringing the reactor back online. NRG has said they expect to provide another HFR update by January 17, and they will provide us at least two weeks' notice prior to any planned restart date. We will communicate further with you as needed as we learn more.

Our supply chain teams in the United States and the Netherlands have worked diligently throughout this situation to ensure our ability to meet current customer demand globally. We have confirmed molybdenum-99 (Mo-99) supply throughout January and well beyond as needed using our diverse supply chain, including additional target irradiation cycles in the Polish Maria reactor.

We are committed to meeting your needs and those of the patients you serve. We anticipate being able to meet 100% of your needs in the coming months, capitalizing on our unique abilities as both a Mo-99 processor and a technetium-99m generator manufacturer combined with the strength of our relationships with our reactor operator partners.

Thank you for allowing us to continue as your nuclear medicine partner. If you have further questions, please contact your Mallinckrodt sales representative or our Customer Service department at 888-744-1414.

Sincerely,

A handwritten signature in black ink, appearing to read "Dan Bague".

Dan Bague
Vice President, Sales and Marketing, Nuclear Medicine
North America